Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire PLC

Division of Takeda Pharmaceutical Co. Ltd.
www.shire.com

Latest From Shire PLC

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

BioMarin’s focus on rare diseases and gene therapies and expected financial growth make it a logical acquisition target for almost any large pharma, though Biogen, Amgen and Regeneron also offer a beneficial fit for many.

M & A Business Strategies

Shire Solid But Hemophilia Challenges Looming?

Shire puts in solid results in last full year before Takeda acquisition, with 4% sales growth and strong cash flow, but there was some weakness in hematology stemming from lower ex-US prices and rising competition.

Business Strategies Commercial

Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals

A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.

Deals Financing

Takeda Says Last Pre-Shire Quarter ‘Robust’, But Quiet On Divestments

Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.

Japan Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register